Interius BioTherapeutics was excited to take part in the Ecosystem-Wide Biotech Jobs Fair 2024 hosted by BioLabs Philadelphia & BioStrategy Partners this week. Thank you to Melina Blees for the invitation to attend! With over 600 people confirmed in attendance and employers ranging from small biotechs to large pharma, the fair underscored the richness of our Philadelphia biotech talent community! #biotechjobsfair #phillybio #biolabs #biotech #cellandgenetherapy #cart #genetherapy #celltherapy
Interius BioTherapeutics
生物技术研究
Philadelphia，Pennsylvania 4,606 位关注者
Interius is developing new ways to engineer cells inside the human body, right where they live
关于我们
Interius is a clinical stage biotechnology company, engineering targeted, programmable vectors for the precision delivery of genetic medicines to treat an array of challenging diseases.
- 网站
-
https://interiusbio.com/
Interius BioTherapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Philadelphia，Pennsylvania
- 类型
- 私人持股
地点
-
主要
获取路线
3401 Grays Ferry Ave
Building 200, Suite 300
US，Pennsylvania，Philadelphia，19146
Interius BioTherapeutics员工
动态
-
Last week, as part of our ongoing effort to create positive impacts in our communities, a group of Interians made the hike out to Wissahickon Park to volunteer for a day of service with Friends of the Wissahickon. The team helped with invasive species removal and trail improvements. Friends of the Wissahickon is celebrating 100 years of stewardship this year, and we are thrilled the Interius team had the opportunity to contribute to the maintenance of this natural preserve for our city!
-
-
-
-
-
+2
-
-
Interius BioTherapeutics will be at the job fair tomorrow! #phillybio
The historic Curtis building has seen a lot of changes in the last 115 years—from a major publishing house to a hub for cutting-edge advanced therapy startups today. Next week, it will mark another milestone. We're excited to host Philadelphia’s first-ever biotech job fair of this scale right here in the heart of the city! With 500+ attendees from both industry and academia and local employers setting up their booths, this is a can’t-miss event for anyone looking to explore new opportunities or take the next step in their biotech career. Link to register: https://lnkd.in/e9JGNUje Join us at this iconic venue, which once housed Curtis Publishing, the powerhouse behind American magazine classics like The Ladies’ Home Journal and The Saturday Evening Post. And while you're here, don’t forget to marvel at the stunning Dream Garden mosaic in the lobby! We are at STEMPeers ?thrilled to be part of the organizing team and we will be volunteering for resume reviews on the spot. Thank you, Melina Blees of BioLabs Philadelphia and Bryan Tsao, PhD of Biostrategy Partners and other stakeholders of Philly biotech to organize this event at this scale. See you there for a day of networking, opportunities, and history in the making. ?? Curtis Building, Philadelphia ?? November 19th 2024 ?? 3:30 PM - 7:00 PM hashtag #PhiladelphiaBiotech #BiotechJobFair #Networking #STEMPeers #CurtisBuilding #PhillyBiotech #DreamGarden
-
-
Thank you to Jonah Comstock and pharmaphorum for asking the "next generation question" - can we make therapeutic effector cells in vivo, where we use the patient's own body to manufacture those cells, as opposed to having to remove the cells from the body first? A direct in vivo approach would forego complex and costly manipulation, provide the ability to treat patients without delay, and, importantly, improve access to potentially transformative therapies. At Interius BioTherapeutics, we are at the forefront of asking, and answering, these questions every day! And we could not do it without our amazing team of Interians! #phillybio #biotech #cellandgenetherapy #cart #genetherapy #celltherapy
-
Thank you to Philadelphia Business Journal and John George for the interview with Interius BioTherapeutics CEO Philip R. Johnson, MD and for spreading the good news in our Philadelphia biotech community about Interius's commitment to taking innovative therapies into the clinic. We appreciate the shoutout to Saar Gill, Interius's scientific co-founder, whose clinical experience inspired the development of our platform for precision delivery of genetic medicines. #phillybio #biotech #cellandgenetherapy #cart #genetherapy #celltherapy
University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - Philadelphia Business Journal
bizjournals.com
-
Thank you to Jonathan D. Grinstein, PhD from Inside Precision Medicine for the publication on Interius BioTherapeutics this week highlighting our platform for precision delivery of genetic medicines and the achievement of the first patient dosed milestone with our lead program. The initiation of the Phase 1 trial for INT2104 is an important step in evaluating the safety of this in vivo CAR investigational product in adults with refractory/relapsing B cell malignancies. We remain thankful to everyone involved in the advancement of our science and programs and in amplifying our message across the biotech innovator community. #phillybio #biotech #cellandgenetherapy #cart #genetherapy #celltherapy
First Patient Dosed with In Vivo Gene Therapy for CAR T
https://www.insideprecisionmedicine.com
-
Today Interius BioTherapeutics announced that the first study participant has been dosed in INVISE, its first-in-human Phase 1 clinical trial of INT2104, a first-in-class gene therapy that delivers a CAR transgene to generate effector CAR-T and CAR-NK cells?in vivo for the targeting of CD20-positive B cells for the treatment of B-cell malignancies. We are grateful for the dedication of all Interians, consultants, partners, and clinicians, who made this milestone a reality. #biotech #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy See press release here: https://lnkd.in/duJA-fja
-
Interius BioTherapeutics is proud to sponsor the ASGCT Advancing Gene + Cell Therapies for Cancer in Philadelphia. Day 1 at the conference was outstanding: Dr. Daniel Powell opened with a reminder that we are Cellicon Valley, and the rest of the day lived up to that banner with presentations on all types of modalities and research ranging from non-clinical stage to meta-analyses of tens of trials. Thank you to the organizers and to Dr. Saar Gill for being a gracious host for the meeting! #ASGCTAdvancing24 #phillybio
Dr. Saar Gill, Advancing Gene + Cell Therapies for Cancer Planning Committee Chair, discusses an exciting shift in the field of adoptive cell therapy: moving from ex-vivo to in-vivo cell modification. This topic will be covered in detail during Thursday's session: "Off the Shelf CAR-T Cells Using Direct In Vivo." "I think this is why the field is so exciting and this is why, if there are positive results, I really think this is going to spur such a huge amount of additional innovation and excitement," said Dr. Gill when discussing the shift of ex-vivo to in-vivo modification of cells. Advancing Gene + Cell Therapies for Cancer kicks off tomorrow morning with a panel discussion hosted by Daniel Powell, PhD, and Nayan Jain, PhD, titled "New Cancer-specific Antigens and Targeting of Intracellular Oncoproteins." Join the discussion, in-person or online. Register at www.asgct.org/advancing.
-
Join Interius BioTherapeutics in Philadelphia next week! Our VP of R&D Tim Culp, PhD, is speaking at #ASGCTAdvancing24. He will be presenting a talk and joining a discussion on in vivo engineering of human immune cells on Oct. 17 at 8:30 a.m. Hope to see you there! #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy
-
-
Listen to Tim Culp, PhD, our VP of Research and Development share his experience, wisdom, and passion for drug development on an Xtalks interview with Vera Kovacevic, PhD. Tim discusses our faster-better-cheaper platform for precision delivery of genetic medicines. While noting its immense future potential, Tim suggest "keeping an eye on the long view"—the ultimate goal is to get these new drugs through licensure and into the lives of patients. Interius BioTherapeutics has taken the first step: our first clinical trial is open and enrolling participants. #biotech #cellandgenetherapy #cart #genetherapy #phillybio #celltherapy
A Unique Approach to in vivo CAR T Therapy and New Advancements in the Field
xtalks.com